|
1
|
DeSantis CE, Fedewa SA, Goding Sauer A,
Kramer JL, Smith RA and Jemal A: Breast cancer statistics, 2015:
Convergence of incidence rates between black and white women. CA
Cancer J Clin. 66:31–42. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Iranshahi N, Zafari P, Yari KH and
Alizadeh E: The most common genes involved in epigenetics
modifications among Iranian patients with breast cancer: A
systematic review. Cell Mol Biol (Noisy-le-grand). 62:116–122.
2016.PubMed/NCBI
|
|
3
|
Araki K and Ito Y: A review multigene
assays for clinical utility in breast cancer. Gan To Kagaku Ryoho.
43:1332–1340. 2016.(In Japanese). PubMed/NCBI
|
|
4
|
Lucius K and Trukova K: Integrative
therapies and cardiovascular disease in the breast cancer
population: A review, part 2. Integr Med (Encinitas). 14:33–40.
2015.PubMed/NCBI
|
|
5
|
Lucius K and Trukova K: Integrative
therapies and cardiovascular disease in the breast cancer
population: A review, part 1. Integr Med (Encinitas). 14:22–29.
2015.PubMed/NCBI
|
|
6
|
Leuteritz K, Weißflog G, Barthel Y,
Brähler E, Zwerenz R, Wiltink J and Beutel ME: Therapeutic alliance
and treatment outcome in psychodynamic psychotherapy of depressed
breast cancer patients: The same old story or different from other
populations? Breast Cancer. 24:765–773. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Moreno Ayala MA, Gottardo MF, Asad AS,
Zuccato C, Nicola A, Seilicovich A and Candolfi M: Immunotherapy
for the treatment of breast cancer. Expert Opin Biol Ther.
17:797–812. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Allaire BT, Ekwueme DU, Poehler D, Thomas
CC, Guy GP Jr, Subramanian S and Trogdon JG: Breast cancer
treatment costs in younger, privately insured women. Breast Cancer
Res Treat. 164:429–436. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Holzel D, Eckel R, Bauerfeind I, Baier B,
Beck T, Braun M, Ettl J, Hamann U, Kiechle M, Mahner S, et al:
Improved systemic treatment for early breast cancer improves cure
rates, modifies metastatic pattern and shortens post-metastatic
survival: 35-year results from the munich cancer registry. J Cancer
Res Clin Oncol. 143:1701–1712. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
An Y, Amr SS, Torres A, Weissman L,
Raffalli P, Cox G, Sheng X, Lip V, Bi W, Patel A, et al: SOX12 and
NRSN2 are candidate genes for 20p13 subtelomeric deletions
associated with developmental delay. Am J Med Genet B
Neuropsychiatr Genet. 162B:832–840. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang XY, Kuang JL, Yan CS, Tu XY, Zhao
JH, Cheng XS and Ye XQ: NRSN2 promotes non-small cell lung cancer
cell growth through PI3K/Akt/mTOR pathway. Int J Clin Exp Pathol.
8:2574–2581. 2015.PubMed/NCBI
|
|
12
|
Tang W, Ren A, Xiao H, Sun H and Li B:
Highly expressed NRSN2 is related to malignant phenotype in ovarian
cancer. Biomed Pharmacother. 85:248–255. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang X, Han L, Zhang J and Xia Q:
Down-regulated NRSN2 promotes cell proliferation and survival
through PI3K/Akt/mTOR pathway in hepatocellular carcinoma. Dig Dis
Sci. 60:3011–3018. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jeong YJ, Choi Y, Shin JM, Cho HJ, Kang
JH, Park KK, Choe JY, Bae YS, Han SM, Kim CH, et al: Melittin
suppresses EGF-induced cell motility and invasion by inhibiting
PI3K/Akt/mTOR signaling pathway in breast cancer cells. Food Chem
Toxicol. 68:218–225. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kuo YY, Jim WT, Su LC, Chung CJ, Lin CY,
Huo C, Tseng JC, Huang SH, Lai CJ, Chen BC, et al: Caffeic acid
phenethyl ester is a potential therapeutic agent for oral cancer.
Int J Mol Sci. 16:10748–10766. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fernandez-Pol S, Ma L, Ohgami RS and Arber
DA: Immunohistochemistry for p53 is a useful tool to identify cases
of acute myeloid leukemia with myelodysplasia-related changes that
are TP53 mutated, have complex karyotype, and have poor prognosis.
Mod Pathol. 30:382–392. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gupta A, Shridhar K and Dhillon PK: A
review of breast cancer awareness among women in India: Cancer
literate or awareness deficit? Eur J Cancer. 51:2058–2066. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Brodsky AS, Xiong J, Yang D, Schorl C,
Fenton MA, Graves TA, Sikov WM, Resnick MB and Wang Y:
Identification of stromal ColXalpha1 and tumor-infiltrating
lymphocytes as putative predictive markers of neoadjuvant therapy
in estrogen receptor-positive/HER2-positive breast cancer. BMC
Cancer. 16:2742016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tan H, Zhang H, Yang W, Fu Y, Gu Y, Du M,
Cheng D and Shi H: Breast-specific gamma imaging with
Tc-99m-sestamibi in the diagnosis of breast cancer and its
semiquantitative index correlation with tumor biologic markers,
subtypes, and clinicopathologic characteristics. Nucl Med Commun.
37:792–799. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Adamczyk A, Niemiec J, Ambicka A,
Mucha-Małecka A, Ryś J, Mituś J, Wysocki WM, Cichocka A and
Jakubowicz J: Survival of breast cancer patients according to
changes in expression of selected markers between primary tumor and
lymph node metastases. Biomark Med. 10:219–228. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Araki K and Miyoshi Y: Mechanism of
resistance to endocrine therapy in breast cancer: The important
role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative
breast cancer. Breast Cancer. 25:392–401. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gutsche K, Randi EB, Blank V, Fink D,
Wenger RH, Leo C and Scholz CC: Intermittent hypoxia confers
pro-metastatic gene expression selectively through NF-κB in
inflammatory breast cancer cells. Free Radic Biol Med. 101:129–142.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Guerrero-Zotano A, Mayer IA and Arteaga
CL: PI3K/AKT/mTOR: Role in breast cancer progression, drug
resistance, and treatment. Cancer Metastasis Rev. 35:515–524. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li Z, Qian J, Li J and Zhu C: Knockdown of
lncRNA-HOTAIR downregulates the drug-resistance of breast cancer
cells to doxorubicin via the PI3K/AKT/mTOR signaling pathway. Exp
Ther Med. 18:435–442. 2019.PubMed/NCBI
|
|
26
|
Liu B, Sun L, Liu Q, Gong C, Yao Y, Lv X,
Lin L, Yao H, Su F, Li D, et al: A cytoplasmic NF-κB interacting
long noncoding RNA blocks IκB phosphorylation and suppresses breast
cancer metastasis. Cancer Cell. 27:370–381. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shen Q, Cohen B, Zheng W, Rahbar R, Martin
B, Murakami K, Lamorte S, Thompson P, Berman H, Zúñiga-Pflücker JC,
et al: Notch shapes the innate immunophenotype in breast cancer.
Cancer Discov. 7:1320–1335. 2017. View Article : Google Scholar : PubMed/NCBI
|
